Phaseline

Companies › Madrigal Pharmaceuticals

Madrigal Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 8 registered trials: 3 Phase 3, 3 Phase 2, 1 Phase 4, 1 Phase 1; Cardiovascular, Gastroenterology, Infectious disease, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Resmetirom
Thyroid hormone receptor beta-1 agonist
THRBPhase 4MASH - Metabolic Dysfunction-Associated Steatohepatitis; NASH; Non-Alcoholic Fatty Liver Disease; NASH - Nonalcoholic Steatohepatitis …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05500222ResmetiromPhase 3NASHGastroenterologyDec 2026
NCT04951219ResmetiromPhase 3Non-Alcoholic Fatty Liver DiseaseMetabolic and endocrineMar 2027
NCT07143968ResmetiromPhase 2MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseInfectious diseaseOct 2027
NCT07848191ResmetiromPhase 4MASH - Metabolic Dysfunction-Associated SteatohepatitisMetabolic and endocrineNov 2027
NCT07830758ResmetiromPhase 1MASH - Metabolic Dysfunction-Associated SteatohepatitisCardiovascularNov 2027
NCT03900429ResmetiromPhase 3NASH - Nonalcoholic SteatohepatitisGastroenterologyJan 2028
NCT07335601ResmetiromPhase 2MASH - Metabolic Dysfunction-Associated SteatohepatitisMetabolic and endocrineAug 2028
NCT07763015ResmetiromPhase 2MASHMetabolic and endocrineJul 2029

From the company's SEC filings

Cash and short-term investments of $961m on 2026-09-30; operating cash outflow about $32m a year; runway about 365 months at that burn, to Feb 2057; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

THRB (1)

Companies with the same targets

Rare Thyroid Therapeutics International AbbVie

Companies built like this

Lexicon Pharmaceuticals Phathom Pharmaceuticals Guangdong Raynovent Biotech vTv Therapeutics Crystalys Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.